Bexxar (Tositumomab and iodine I 131 tositumomab) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Bexxar is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with CD20­-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed after treatment with rituximab. Bexxar is also referred to by its drug name, tositumomab and iodine I 131 tositumomab.

Bexxar is a biologic therapy for lymphoma. Bexxar is a member of a class of drugs called monoclonal antibodies. Bexxar is believed to work by targeting malignant B cells.

How do I take it?
Prescribing information states that Bexxar is administered intravenously in two separate steps, separated by 7 to 14 days.

Bexxar comes in the form of an intravenous infusion.

Side effects
The FDA-approved label for Bexxar lists common side effects including decreased blood counts, reactions to the infusion, tiredness or decreased energy, fever, and nausea.

Rare but serious side effects listed for Bexxar include serious allergic reactions, other cancer, fetal harm in pregnant women, and hypothyroidism.

For more details about this treatment, visit:

Bexxar — RxList

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in